预约演示
更新于：2026-11-09
[68Ga] Pentixafor
更新于：2026-11-09
概要
基本信息
药物类型 多肽偶联核素、诊断用放射药物 |
别名 [68Ga]Ga-PentixaFor、Gallium (68Ga) boclatixafortide、PentixaFor + [3] |
作用方式 拮抗剂 |
作用机制 CXCR4拮抗剂(C-X-C基序趋化因子受体4拮抗剂)、αvβ3拮抗剂(整合素α-V/β-3复合体拮抗剂) |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床前 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 525682907
来源: *****
关联
30
项与 [68Ga] Pentixafor 相关的临床试验NCT07007325
Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression
CTRI/2026/04/108288
Prospective Study to evaluate the Role of a Novel Imaging Study - 68 Ga PENtixafor PET/CT toDetect Residual Disease in Multiple Myeloma - ProPEN
NCT07350707
CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study
100 项与 [68Ga] Pentixafor 相关的临床结果
登录后查看更多信息
100 项与 [68Ga] Pentixafor 相关的转化医学
登录后查看更多信息
100 项与 [68Ga] Pentixafor 相关的专利（医药）
登录后查看更多信息
128
项与 [68Ga] Pentixafor 相关的文献（医药）2026-11-01JOURNAL OF NUCLEAR MEDICINE
CXCR4-Targeted Molecular Imaging in Hematology and Oncology
Review
作者: Lapa, Constantin ; Kraeber-Bodéré, Francoise ; Buck, Andreas K ; Bodet-Milin, Caroline ; Deroose, Christophe M ; Gotthardt, Martin ; Schottelius, Margret ; Haug, Alexander ; Keller, Ulrich ; Wegen, Simone ; Herrmann, Ken ; Kobe, Carsten ; Higuchi, Takahiro ; Werner, Rudolf A ; Serfling, Sebastian E ; Pomper, Martin G ; Raderer, Markus
C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a powerful imaging target in nuclear oncology. In this regard, the PET agent [68Ga]Ga-pentixafor is promising but still evolving. In this article, we provide an overview of potentially useful imaging applications for CXCR4-targeted imaging in hemato-oncology and guidance on scan interpretation by discussing diagnostic pitfalls. We also report on theranostic efforts and how the field has been expanded toward the imaging of solid tumors. As such, this review focuses on potential clinical integration of CXCR4-targeted molecular imaging across multiple disease entities, particularly in the field of hemato-oncology.
2026-10-01CLINICAL NUCLEAR MEDICINE
Heterogeneity and Evolution of 68Ga-Pentixafor PET/CT Signals in Extramedullary Multiple Myeloma
Article
作者: Ma, Lingyu ; Kang, Fei ; Ji, Mengjing ; Ye, Yutong
A 55-year-old man with multiple myeloma (MM) underwent
68
Ga-pentixafor PET/CT. An extramedullary soft-tissue lesion was initially misdiagnosed as a mesenchymal tumor due to low tracer avidity and marked uptake heterogeneity (bone marrow SUVmax 21.8 vs. extramedullary lesion SUVmax 4.1). The patient received standard anti-myeloma therapy for presumed medullary-limited MM. After 4 months, bone marrow disease was controlled, but the isolated extramedullary soft-tissue lesion showed increased
68
Ga-pentixafor uptake and enlarged size. Immunohistochemistry confirmed the extramedullary lesion to be an extramedullary disease (EMD) originating from MM. This case highlights the diagnostic challenges of low-CXCR4-avid extramedullary lesions.
2026-09-01European Journal of Nuclear Medicine and Molecular Imaging
CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG
Article
作者: Hu, Haoyuan ; Zou, Liqun ; Jiang, Ming ; Tian, Rong ; Huang, Hexiao ; Xiang, Yongzhao ; Gao, Limin ; Liu, Yunyi ; Li, Xin ; Zhang, Zitong ; Jiang, Chong
BACKGROUND:
Marginal zone lymphoma (MZL) exhibits substantial clinical heterogeneity, necessitating accurate whole-body tumor burden assessment and early risk stratification. However, conventional [18F]FDG PET/CT is limited in both anatomical staging and in vivo biological characterization. This prospectively recruiting study conducted a head-to-head comparison of the CXCR4-targeted tracer [68Ga]Ga-PentixaFor and [18F]FDG in treatment-naïve patients to evaluate their complementary value in improving staging accuracy and their association with early treatment response.
METHODS:
Forty-one treatment-naïve MZL patients prospectively underwent dual-tracer PET/CT prior to therapy. Lesion detection rates, stage migration, and management modifications were systematically assessed. The prognostic value of baseline imaging parameters for interim treatment response was also analyzed.
RESULTS:
[68Ga]Ga-PentixaFor demonstrated significantly higher lesion detection rates than [18F]FDG, particularly for gastric (72.0% vs. 40.0%) and nodal involvement (97.4% vs. 39.7%), with a superior target-to-background ratio (median TBRliver: 5.55 vs. 2.42, p < 0.01). CXCR4-targeted imaging resulted in disease upstaging in 26.8% of patients (overall stage migration: 29.3%) and led to management modifications in 56.1%. Regarding therapeutic outcomes, higher baseline [68Ga]Ga-PentixaFor SUVmax (> 7.96) was associated with lower complete remission (CR) rates. Notably, dual-tracer phenotyping further demonstrated decreasing CR rates across double-negative, single-positive, and double-positive groups (100%, 61.5%, and 36.4%, respectively).
CONCLUSION:
[68Ga]Ga-PentixaFor PET/CT significantly outperforms [18F]FDG in initial staging of MZL and has a substantial impact on clinical management. Importantly, dual-tracer imaging shows potential as a novel, non-invasive biomarker for in vivo phenotypic characterization, which is associated with early therapeutic outcomes and the identification of high-risk patients.
25
项与 [68Ga] Pentixafor 相关的新闻（医药）2026-11-08
优先审批抗体药物偶联物引进/卖出临床3期疫苗
2026-09-23
100 项与 [68Ga] Pentixafor 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 边缘区B细胞淋巴瘤 | 临床3期 | 奥地利 | 2024-05-20 | |
| 边缘区B细胞淋巴瘤 | 临床3期 | 法国 | 2024-05-20 | |
| 边缘区B细胞淋巴瘤 | 临床3期 | 德国 | 2024-05-20 | |
| 边缘区B细胞淋巴瘤 | 临床3期 | 意大利 | 2024-05-20 | |
| 边缘区B细胞淋巴瘤 | 临床3期 | 西班牙 | 2024-05-20 | |
| 醛固酮增多症 | 临床3期 | - | - | |
| 原发性中枢神经系统淋巴瘤 | 临床2期 | 丹麦 | 2022-10-05 | |
| 原发性中枢神经系统淋巴瘤 | 临床2期 | 法国 | 2022-10-05 | |
| 继发性中枢神经系统淋巴瘤 | 临床2期 | 丹麦 | 2022-10-05 | |
| 继发性中枢神经系统淋巴瘤 | 临床2期 | 法国 | 2022-10-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 多发性骨髓瘤 一线 | 25 | (Patients with decline in SUVmax of bone marrow < 40%) | 獵範顧膚蓋廠鏇築願襯(顧窪蓋鹽鏇醖蓋窪積夢) = 製壓獵艱觸夢蓋膚淵鹹 淵鹽壓構鏇廠獵鬱積廠 (廠積廠製蓋製鬱鏇構憲, 20.8 ~ 42.8) 更多 | - | 2025-06-20 | |
(Patients with visually reduced splenic uptake in follow-up PET/CT) | 獵範顧膚蓋廠鏇築願襯(顧窪蓋鹽鏇醖蓋窪積夢) = 積鹹糧齋鹹鬱齋襯夢蓋 淵鹽壓構鏇廠獵鬱積廠 (廠積廠製蓋製鬱鏇構憲, 18.5 ~ 31.9) 更多 | ||||||
临床1期 | 19 | (AVS) | 顧鏇遞夢齋獵艱鏇觸顧(遞襯餘築窪顧鏇襯繭艱) = 齋憲廠顧齋膚膚鹽糧蓋 艱觸繭選簾齋繭齋積衊 (顧願範餘糧壓鑰繭淵衊 ) | - | 2023-06-01 | ||
N/A | - | (68Ga-Pentixafor PET/CT) | 觸願廠網襯憲夢鏇簾網(蓋積糧膚選鏇糧鹽蓋窪) = 網淵網獵艱網廠繭淵簾 齋襯遞鑰艱憲淵繭鹽醖 (衊憲艱獵蓋廠遞糧鏇積, 12.1 ~ 16.4) | - | 2022-08-08 | ||
早期临床1期 | - | (<sup>18</sup>F-FDG PET/CT) | 窪積觸鏇艱襯鏇窪築觸(範觸膚獵憲築壓遞製夢) = 衊窪築獵蓋壓構鹽窪蓋 窪衊夢獵蓋遞鏇壓製獵 (範構網選觸艱構繭網鑰 ) | - | 2020-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用